Neurosense Therapeutics Ltd. - (NRSN) closed at $3.07 on October 16, 2026, down 3.2% from the previous close, on volume of 9,646 shares (30-day average 225,538).
Data as of October 16, 2026.
NRSN sets Nov. 10 Nasdaq hearing as PrimeC milestones line up into Q1 2027
Market Chameleon (Wed, 14-Oct 7:05 AM ET)
Market Chameleon (Tue, 13-Oct 7:47 AM ET)
NeuroSense Wins Nasdaq Hearing Date as PrimeC Nears Key Regulatory and Funding Milestones
TipRanks (Tue, 13-Oct 8:57 AM ET)
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
PRNewswire (Tue, 13-Oct 8:31 AM ET)
NeuroSense Provides Update on Nasdaq Listing Compliance
PRNewswire (Fri, 2-Oct 4:15 PM ET)
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
PRNewswire (Mon, 28-Sep 12:44 PM ET)
NeuroSense Provides Business Update and Progress for the First Half of 2026
PRNewswire (Fri, 25-Sep 4:30 PM ET)
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
PRNewswire (Thu, 10-Sep 9:00 AM ET)
PRNewswire (Mon, 31-Aug 8:45 AM ET)
NeuroSense Issues CEO Letter to Shareholders
PRNewswire (Thu, 13-Aug 9:32 AM ET)
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Neurosense Therapeutics Ltd. - trades on the NASDAQ stock market under the symbol NRSN.
As of October 16, 2026, NRSN stock price declined to $3.07 with 9,646 million shares trading.
NRSN has a beta of 2.31, meaning it tends to be more sensitive to market movements. NRSN has a correlation of 0.07 to the broad based SPY ETF.
NRSN has a market cap of $5.82 million. This is considered a Sub-Micro Cap stock.
Last quarter Neurosense Therapeutics Ltd. - reported $0 in Revenue and -$2.10 earnings per share. This fell short of revenue expectation by $-514,000 and missed earnings estimates by -$2.02.
In the last 3 years, NRSN traded as high as $52.00 and as low as $2.87.
NRSN has underperformed the market in the last year with a price return of -87.4% while the SPY ETF gained +16.7%. NRSN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -78.1% and -22.0%, respectively, while the SPY returned +1.9% and -0.8%, respectively.
NRSN support price is $2.85 and resistance is $3.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRSN shares will trade within this expected range on the day.
